Pyrazinamide 500mg is a potent, first-line antituberculosis medication and a critical component of short-course combination therapy for Tuberculosis (TB). It is indicated for the treatment of all forms of pulmonary and extrapulmonary tuberculosis, working synergistically with other anti-TB drugs like Rifampicin, Isoniazid, and Ethambutol to ensure the complete eradication of the infection.
What makes Pyrazinamide unique is its exceptional ability to target and kill semi-dormant Mycobacterium tuberculosis bacteria that other drugs often cannot reach, particularly those hiding within the acidic environment of immune cells (macrophages). By eliminating these “stubborn” bacteria during the initial intensive phase of treatment, Pyrazinamide significantly shortens the overall duration of therapy from 9–12 months to just 6 months, reducing the risk of relapse and the development of drug-resistant TB.
Key Benefits:
-
Accelerated TB Recovery: Effectively shortens the treatment period when used in the intensive phase (first 2 months).
-
Targeted Bacterial Eradication: Specifically kills dormant bacteria to prevent future flare-ups and relapses.
-
Essential 1st-Line Therapy: A standard requirement in the WHO-recommended DOTS (Directly Observed Treatment, Short-course) program.
-
Comprehensive Protection: Helps stop the spread of infection by rapidly reducing the bacterial load in the body.
-
Cost-Effective Management: Provides a reliable and affordable solution for long-term respiratory health.





